Subscribe To
HRMY / HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
![HRMY vs. REGN: Which Stock Should Value Investors Buy Now?](https://cdn.snapi.dev/images/v1/y/r/default15-2139553.jpg)
HRMY News
![HRMY vs. REGN: Which Stock Should Value Investors Buy Now? HRMY vs. REGN: Which Stock Should Value Investors Buy Now?](https://cdn.snapi.dev/images/v1/y/r/default15-2139553.jpg)
By Zacks Investment Research
November 3, 2023
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Rege more_horizontal
![Harmony Stock Tanks On Study Miss For Narcolepsy Drug: Problems May Be Escalating Harmony Stock Tanks On Study Miss For Narcolepsy Drug: Problems May Be Escalating](https://cdn.snapi.dev/images/v1/4/w/image-1006853456-2103201.jpg)
By Seeking Alpha
October 13, 2023
Harmony Stock Tanks On Study Miss For Narcolepsy Drug: Problems May Be Escalating
Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings more_horizontal
![Why Shares of Harmony Bioscience Are Falling on Friday Why Shares of Harmony Bioscience Are Falling on Friday](https://cdn.snapi.dev/images/v1/d/i/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7509342fsenior-patient-looking-through-window-at-hospitaljpgopresizew400h400-2102969.jpg)
By The Motley Fool
October 13, 2023
Why Shares of Harmony Bioscience Are Falling on Friday
Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter reven more_horizontal
![Harmony Biosciences stock drops on disappointing study results Harmony Biosciences stock drops on disappointing study results](https://cdn.snapi.dev/images/v1/e/k/2023-05-11-10-14-52-ba3bf1d0f7fd15ca442d52e3cb00f4a0-6529623682031-2102813.jpg)
By Proactive Investors
October 13, 2023
Harmony Biosciences stock drops on disappointing study results
Harmony Biosciences Holdings Inc shares sank 38% to $18.66 in late-morning trading on Friday after the pharmaceutical company reported topline results more_horizontal
![Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep](https://cdn.snapi.dev/images/v1/9/g/image-1472399442-2075487.jpg)
By Seeking Alpha
September 24, 2023
Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep
Harmony Biosciences has experienced strong and profitable growth following the approval and commercialization of WAKIX. The company's success has allo more_horizontal
![HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE](https://cdn.snapi.dev/images/v1/f/c/conf11-2061334.jpg)
By PRNewsWire
September 13, 2023
HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , Sept. 13, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutica more_horizontal
![Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million](https://cdn.snapi.dev/images/v1/i/v/biotech7-2021638.jpg)
By Market Watch
August 14, 2023
Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million
Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would more_horizontal
![Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates](https://cdn.snapi.dev/images/v1/b/b/default26-1999179.jpg)
By Zacks Investment Research
August 1, 2023
Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.62 per share more_horizontal